pharma news today obesity drugs glp-1 october 2025 trends 2025: real-world data, patient outcomes & future therapies GLP-1 Overdoses Are Rising as

This is a huge market

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection

Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62

The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro

Repatha (evolocumab) is a PCSK9 inhibitor that cuts LDL by ~60% when statins aren't enough

This supplement fits seamlessly into any lifestyle, encouraging regular use alongside balanced nutrition and active habits to help maximize sustainable, long-term wellness results.